← Back to Search
Proteasome Inhibitor
Carfilzomib + Pomalidomide + Dexamethasone for Multiple Myeloma
Atlanta, GA
Phase 2
Waitlist Available
Led By Ajay Nooka, MD, MPH
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking pomalidomide through 90 days after the last dose of study drug
Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1
Must not have
Diagnosed with specific conditions including smoldering multiple myeloma (MM), monoclonal gammopathy of undetermined significance, Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, amyloidosis or standard risk myeloma or secondary plasma cell leukemia
Known significant cardiac abnormalities
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first dose until documented progression or death, assessed at 18 months
Awards & highlights
No Placebo-Only Group
All Individual Drugs Already Approved
Approved for 100 Other Conditions
Summary
This trial will study how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma.
See full description
Who is the study for?
This trial is for adults with high-risk multiple myeloma who've possibly had a stem cell transplant and responded to treatment. They must be able to follow the study plan, use effective birth control, and not have other serious health issues or recent major surgeries. People with certain heart conditions, infections like HIV or hepatitis B/C, previous cancers (except some skin/cervical), allergies to study drugs, or poor reaction to steroids can't join.Check my eligibility
What is being tested?
The trial tests a combination of three drugs: Carfilzomib (blocks enzymes needed for cancer cells growth), Pomalidomide and Dexamethasone (both chemotherapy agents that kill or stop cancer cells from growing). It aims to see if this mix works better for those with aggressive multiple myeloma.See study design
What are the potential side effects?
Possible side effects include fatigue, nausea, risk of infection due to low blood counts, allergic reactions to the medication components, potential heart complications related to Carfilzomib usage, nerve damage symptoms like numbness or tingling sensations.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am committed to using two forms of birth control before, during, and after taking pomalidomide.
show original
Select...
I am fully active or can carry out light work.
show original
Select...
I am a woman capable of becoming pregnant.
show original
Select...
I had a stem cell transplant within a year of my diagnosis and my condition has partially improved.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been diagnosed with a specific blood or bone marrow condition.
show original
Select...
I have known serious heart problems.
show original
Select...
I have had a stroke or brain injury that still affects me.
show original
Select...
I had major surgery less than 4 weeks ago or am still dealing with its side effects.
show original
Select...
I am currently pregnant or breastfeeding.
show original
Select...
I do not have any serious illnesses like uncontrolled diabetes or active infections.
show original
Select...
I cannot take certain blood thinners due to allergies or side effects.
show original
Select...
I am currently undergoing or have previously had treatment for myeloma.
show original
Select...
I have a known brain or spinal cord condition.
show original
Select...
I am at high risk and did not reach partial remission after my stem cell transplant.
show original
Select...
I am allergic or react badly to the study drugs or similar medications.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from first dose until documented progression or death, assessed at 18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first dose until documented progression or death, assessed at 18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
≥ Complete response (CR) rates
Secondary study objectives
Best response on-study
Duration of response (DOR)
Minimal residual disease (MRD) detection
+3 moreSide effects data
From 2021 Phase 3 trial • 126 Patients • NCT0302923462%
Anaemia
49%
Upper respiratory tract infection
49%
Platelet count decreased
39%
White blood cell count decreased
38%
Hypertension
35%
Hypokalaemia
30%
Neutrophil count decreased
28%
Lymphocyte count decreased
23%
Pneumonia
21%
Cough
19%
Insomnia
19%
Blood creatinine increased
18%
Pyrexia
17%
Diarrhoea
17%
Hyperuricaemia
16%
Neutrophil count increased
16%
Blood lactate dehydrogenase increased
16%
Hypoalbuminaemia
16%
Hypocalcaemia
15%
Blood pressure increased
15%
Blood uric acid increased
15%
Lung infection
14%
Constipation
14%
Blood bilirubin increased
14%
Blood glucose increased
14%
White blood cell count increased
14%
Hyperglycaemia
12%
Blood urea increased
12%
Neutrophil percentage increased
11%
Alanine aminotransferase increased
11%
Hyponatraemia
11%
Hypercalcaemia
10%
Oedema peripheral
10%
Bronchitis
10%
Aspartate aminotransferase increased
10%
Lymphocyte percentage decreased
10%
Neuropathy peripheral
10%
Productive cough
10%
Blood potassium decreased
9%
Leukocytosis
8%
Hypoproteinaemia
8%
Influenza
8%
Blood albumin decreased
8%
Blood phosphorus increased
7%
Abdominal distension
7%
Vomiting
7%
Peripheral swelling
7%
Nasopharyngitis
7%
Bilirubin conjugated increased
7%
Mean cell volume increased
7%
Prealbumin decreased
7%
Hypophosphataemia
7%
Back pain
7%
Cataract
6%
Vision blurred
6%
Thrombocytopenia
6%
Nausea
6%
Hepatic function abnormal
6%
Respiratory tract infection
6%
Gamma-glutamyltransferase increased
6%
Hypoglycaemia
6%
Hyperkalaemia
3%
Acute kidney injury
3%
Plasma cell myeloma
2%
Localised infection
2%
Cardiac amyloidosis
2%
Bone pain
1%
Otitis media
1%
Obstructive airways disorder
1%
Hypotension
1%
Pancreatitis acute
1%
Lipoma
1%
Bronchiolitis
1%
Device related infection
1%
Escherichia sepsis
1%
Periodontitis
1%
Chronic kidney disease
1%
Dysuria
1%
Asthma
1%
Interstitial lung disease
1%
Organising pneumonia
1%
Pleural effusion
1%
Deep vein thrombosis
1%
Cerebral ischaemia
1%
Nerve compression
1%
Myolipoma
1%
Neuralgia
1%
Cardiac failure acute
1%
Supraventricular tachycardia
1%
Disease progression
1%
Infusion site extravasation
1%
Pain
1%
Soft tissue infection
1%
Spinal compression fracture
1%
Pathological fracture
1%
Myelopathy
100%
80%
60%
40%
20%
0%
Study treatment Arm
Carfilzomib With Dexamethasone
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 100 Other Conditions
This treatment demonstrated efficacy for 100 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Carfilzomib, pomalidomide, dexamethasoneExperimental Treatment3 Interventions
Patients receive carfilzomib IV over 30 minutes on days 1, 8, and 15, pomalidomide PO daily on days 1-21, and dexamethasone PO daily on days 1, 8, and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carfilzomib
FDA approved
Dexamethasone
FDA approved
Pomalidomide
FDA approved
Find a Location
Closest Location:Emory University Hospital/Winship Cancer Institute· Atlanta, GA
Who is running the clinical trial?
National Institutes of Health (NIH)NIH
2,893 Previous Clinical Trials
8,051,914 Total Patients Enrolled
16 Trials studying Multiple Myeloma
897 Patients Enrolled for Multiple Myeloma
Emory UniversityLead Sponsor
1,732 Previous Clinical Trials
2,606,898 Total Patients Enrolled
27 Trials studying Multiple Myeloma
1,916 Patients Enrolled for Multiple Myeloma
AmgenIndustry Sponsor
1,506 Previous Clinical Trials
1,432,939 Total Patients Enrolled
98 Trials studying Multiple Myeloma
22,636 Patients Enrolled for Multiple Myeloma
National Cancer Institute (NCI)NIH
14,068 Previous Clinical Trials
41,160,074 Total Patients Enrolled
596 Trials studying Multiple Myeloma
191,890 Patients Enrolled for Multiple Myeloma
Ajay Nooka, MD, MPHPrincipal Investigator - Emory University
Emory University Hospital, Emory University Hospital Midtown
Andhra Medical College (Medical School)
Canton Medical Educ Fndn (Residency)
2 Previous Clinical Trials
146 Total Patients Enrolled
2 Trials studying Multiple Myeloma
146 Patients Enrolled for Multiple Myeloma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is low, with a creatinine clearance under 30 mL/min.Your platelet count is less than 75,000 cells/mm³ when checked at the screening evaluation.I have known serious heart problems.I have had a stroke or brain injury that still affects me.You have had a bad reaction to steroid medication in the past.I had major surgery less than 4 weeks ago or am still dealing with its side effects.I am currently pregnant or breastfeeding.I do not have any serious illnesses like uncontrolled diabetes or active infections.I cannot take certain blood thinners due to allergies or side effects.Your liver enzyme levels are more than three times the normal limit within 21 days before starting the treatment.I am committed to using two forms of birth control before, during, and after taking pomalidomide.Patients with a disease that is considered to have a high chance of causing serious health problems based on specific criteria.Your body has very low levels of a type of white blood cells called neutrophils.I have been diagnosed with a specific blood or bone marrow condition.I am fully active or can carry out light work.I haven't had cancer in the last 5 years, except for certain skin cancers or cervical cancer that didn't spread.Your bilirubin level is higher than the normal range allowed by the hospital within 21 days before starting the treatment.I am currently undergoing or have previously had treatment for myeloma.I have a known brain or spinal cord condition.Your hemoglobin level is less than 8.0 g/dL when screened.I am at high risk and did not reach partial remission after my stem cell transplant.I agree to use a condom during sex for 90 days after my last dose.I will not donate sperm for 3 months after my last dose of carfilzomib or pomalidomide.I am allergic or react badly to the study drugs or similar medications.I have tested negative for pregnancy before starting pomalidomide.I agree not to donate blood during and for 3 months after treatment.I have moderate to severe nerve damage in my hands or feet.I am a woman capable of becoming pregnant.I had a stem cell transplant within a year of my diagnosis and my condition has partially improved.
Research Study Groups:
This trial has the following groups:- Group 1: Carfilzomib, pomalidomide, dexamethasone
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 100 Other Conditions - This treatment demonstrated efficacy for 100 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.